DK0651799T3 - Fibrinbindende domæne-polypeptider, anvendelser heraf og fremgangsmåder til fremstilling heraf - Google Patents

Fibrinbindende domæne-polypeptider, anvendelser heraf og fremgangsmåder til fremstilling heraf

Info

Publication number
DK0651799T3
DK0651799T3 DK91911888T DK91911888T DK0651799T3 DK 0651799 T3 DK0651799 T3 DK 0651799T3 DK 91911888 T DK91911888 T DK 91911888T DK 91911888 T DK91911888 T DK 91911888T DK 0651799 T3 DK0651799 T3 DK 0651799T3
Authority
DK
Denmark
Prior art keywords
fibrin
polypeptides
methods
binding domain
binding
Prior art date
Application number
DK91911888T
Other languages
Danish (da)
English (en)
Inventor
Amos Panet
Jacob Hartman
Hadassa Shaked
Tikva Vogel
Avigdor Levanon
Moshe Werber
Rachel Guy
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of DK0651799T3 publication Critical patent/DK0651799T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
DK91911888T 1990-05-21 1991-05-21 Fibrinbindende domæne-polypeptider, anvendelser heraf og fremgangsmåder til fremstilling heraf DK0651799T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/526,397 US5270030A (en) 1988-12-29 1990-05-21 Fibrin binding domain polypeptide and method of producing
PCT/US1991/003584 WO1991017765A1 (fr) 1990-05-21 1991-05-21 Polypeptides a domaine de liaison de la fibrine et utilisation et procedes de production desdits polypeptides

Publications (1)

Publication Number Publication Date
DK0651799T3 true DK0651799T3 (da) 2000-03-06

Family

ID=24097174

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91911888T DK0651799T3 (da) 1990-05-21 1991-05-21 Fibrinbindende domæne-polypeptider, anvendelser heraf og fremgangsmåder til fremstilling heraf

Country Status (17)

Country Link
US (4) US5270030A (fr)
EP (1) EP0651799B1 (fr)
JP (1) JP3419772B2 (fr)
AT (1) ATE183545T1 (fr)
AU (1) AU660618B2 (fr)
CA (1) CA2083271C (fr)
DE (1) DE69131539T2 (fr)
DK (1) DK0651799T3 (fr)
ES (1) ES2137928T3 (fr)
FI (1) FI108298B (fr)
GR (1) GR3031708T3 (fr)
HU (1) HU216302B (fr)
IL (1) IL98197A0 (fr)
NO (1) NO310559B1 (fr)
NZ (1) NZ238208A (fr)
RU (1) RU2109750C1 (fr)
WO (1) WO1991017765A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US7087722B1 (en) * 1988-12-29 2006-08-08 Savient Pharmaceuticals, Inc. Fibrin binding domain polypeptides and uses and methods of producing same
US5679320A (en) * 1988-12-29 1997-10-21 Bio-Technology General Corp. Fibrin binding domain polypeptides and uses and methods of producing same
FI924964A0 (fi) * 1990-05-04 1992-11-03 Isis Pharmaceuticals Inc Modulering av genexpression genom stoerande inverkan pao sekundaerstrukturen hos rna
US5792742A (en) * 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
CA2110283A1 (fr) * 1992-03-31 1993-10-14 Tatsutoshi Nakahata Proteine ayant une activite physiologique et agent de croissance des cellules souches hematopoietiques
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
DK145092D0 (fr) * 1992-12-03 1992-12-03 Novo Nordisk As
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US5750088A (en) 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US6288214B1 (en) * 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
IL139385A (en) * 1998-05-15 2005-09-25 Amersham Plc Labelled glutamine and lysine analogues, metal complexes thereof, and uses thereof for diagnosis
IN190822B (fr) 1998-12-24 2003-08-23 Council Scient Ind Res
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
US6426145B1 (en) 1999-05-20 2002-07-30 Scimed Life Systems, Inc. Radiopaque compositions for visualization of medical devices
US6254852B1 (en) 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US6685914B1 (en) * 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
CN1246333C (zh) * 2000-09-07 2006-03-22 舍林股份公司 EDb－纤粘连蛋白结构域(II)的受体
US6714808B2 (en) * 2000-10-03 2004-03-30 University Of Arkansas Method for detecting and excising nonpalpable lesions
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121314A1 (en) * 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in containers
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US20030224476A1 (en) * 2002-03-01 2003-12-04 Szu-Yi Chou Method of producing transglutaminase reactive compound
JP2006516193A (ja) 2002-12-06 2006-06-29 アイシス・ファーマシューティカルス・インコーポレーテッド ヒトおよび動物における病原体の迅速な同定方法
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
JP4755113B2 (ja) 2004-01-30 2011-08-24 クアーク・ファーマスーティカルス、インコーポレイテッド 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
EP2458619B1 (fr) 2004-05-24 2017-08-02 Ibis Biosciences, Inc. Spectrométrie de masse avec filtration sélective d'ions par établissement de seuils numériques
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
JP4468989B2 (ja) 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１阻害剤の治療への使用
WO2006135400A2 (fr) 2004-08-24 2006-12-21 Isis Pharmaceuticals, Inc. Procedes pour l'identification rapide d'organismes recombinants
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2006094238A2 (fr) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions utilisees pour identifier des virus secondaires
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
JP5162447B2 (ja) * 2005-04-13 2013-03-13 アイビス バイオサイエンシズ インコーポレイティッド アデノウイルスの同定に用いる組成物
US7414254B2 (en) * 2005-06-28 2008-08-19 United Pharmacy Partners, Inc. Tungsten pig for radio-pharmaceuticals
CA2616281C (fr) 2005-07-21 2014-04-22 Isis Pharmaceuticals, Inc. Procede pour l'identification et la quantification rapide de variants d'acide nucleique
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
JP5420412B2 (ja) 2006-09-14 2014-02-19 アイビス バイオサイエンシズ インコーポレイティッド 病原体の同定のための標的全ゲノム増幅方法
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
JP5680304B2 (ja) 2007-02-23 2015-03-04 アイビス バイオサイエンシズ インコーポレイティッド 迅速な法医学的ｄｎａ分析法
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
AU2008306455C1 (en) 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
JP5524189B2 (ja) 2008-06-06 2014-06-18 クォーク ファーマシューティカルズ インコーポレーティッド 耳障害治療のための組成物および方法
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
WO2010033599A2 (fr) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Cartouches de mélange, postes de mélange et kits, systèmes et procédés associés
EP2344893B1 (fr) 2008-09-16 2014-10-15 Ibis Biosciences, Inc. Systèmes et procédés de manipulation de microplaques
US8864821B2 (en) 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
WO2010080452A2 (fr) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. Composés d'arnsi et leurs procédés d'utilisation
EP2396803A4 (fr) 2009-02-12 2016-10-26 Ibis Biosciences Inc Ensembles sonde d'ionisation
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
ES2628739T3 (es) 2009-10-15 2017-08-03 Ibis Biosciences, Inc. Amplificación por desplazamiento múltiple
DK2504435T3 (da) 2009-11-26 2019-12-09 Quark Pharmaceuticals Inc Sirna-forbindelser omfattende terminale substitutioner
EP2510098B1 (fr) 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Méthodes et compositions utilisées pour le traitement de maladies, d'affections ou de lésions du snc
WO2011084193A1 (fr) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Composés oligonucléotidique comportant des extrémités sortantes non nucléotidiques
KR101553753B1 (ko) 2010-06-24 2015-09-16 쿠아크 파마수티칼스 인코퍼레이티드 Ｒｈｏａ에 대한 이중 가닥 ｒｎａ 및 그의 용도
AU2011338682B2 (en) 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
CN103562387A (zh) 2011-03-03 2014-02-05 夸克医药公司 Toll样受体途径的寡核苷酸调剂
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
JP6118331B2 (ja) 2011-11-03 2017-04-19 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 神経保護のための方法および組成物
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
EP2802657B1 (fr) 2012-01-12 2018-05-02 Quark Pharmaceuticals, Inc. Polythérapie destinée au traitement de troubles de l'audition et de l'équilibre
DK2895608T3 (en) 2012-09-12 2019-01-21 Quark Pharmaceuticals Inc DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT
US9611473B2 (en) 2012-09-12 2017-04-04 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof
EP3027223A1 (fr) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Procédés d'utilisation de composés sphingolipide-polyalkylamine-oligonucléotide
US9889200B2 (en) 2013-07-31 2018-02-13 Qbi Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
WO2016054079A1 (fr) 2014-09-29 2016-04-07 Zyomed Corp. Systèmes et procédés pour la détection et la mesure du glucose sanguin du sang et d'autres analytes à l'aide du calcul de collision
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
EP3671511B1 (fr) 2018-12-19 2022-07-06 Rohde & Schwarz GmbH & Co. KG Système et procédé de communication
EP3922720A1 (fr) 2020-06-09 2021-12-15 Universidad de Murcia Thérapie pour empêcher un remodelage cardiaque indésirable après un infarctus aigu du myocarde
ES2894201B2 (es) * 2020-08-05 2022-09-29 Fundacion Para La Investig Biomedica Del Hospital Gregorio Maranon Compuestos radioactivos basados en proteinas selectivas de bacterias para la deteccion no invasiva de focos infecciosos

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315906A (en) * 1979-05-21 1982-02-16 New England Nuclear Corporation Cold insoluble globulin, its purification and use
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
US4663146A (en) * 1983-07-29 1987-05-05 Codon Genetic Engineering Laboratories Methods and compositions for the diagnosis of bloodclots using plasminogen activator
US4587122A (en) * 1985-04-23 1986-05-06 The Green Cross Corporation Fibronectin-dextran-drug complex and method of preparation thereof
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
AU2258788A (en) * 1987-07-07 1989-01-30 Cytrx Biopool Ltd. Fibrin-binding compound and method
US4839464A (en) * 1987-08-25 1989-06-13 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
JP2561122B2 (ja) * 1988-04-13 1996-12-04 寳酒造株式会社 機能性ポリペプチド
JP2561131B2 (ja) * 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
AU636596B2 (en) * 1988-12-29 1993-05-06 Savient Pharmaceuticals, Inc. Cloning and production of polypeptide analogs of human fibronectin and method of using such polypeptide analogs
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5026537A (en) * 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque

Also Published As

Publication number Publication date
IL98197A0 (en) 1992-06-21
AU660618B2 (en) 1995-07-06
ATE183545T1 (de) 1999-09-15
NO310559B1 (no) 2001-07-23
EP0651799A1 (fr) 1995-05-10
DE69131539D1 (de) 1999-09-23
NO924405D0 (no) 1992-11-13
CA2083271C (fr) 2002-04-09
FI925296A0 (fi) 1992-11-20
NO924405L (no) 1993-01-13
HUT66189A (en) 1994-10-28
US5455158A (en) 1995-10-03
GR3031708T3 (en) 2000-02-29
ES2137928T3 (es) 2000-01-01
DE69131539T2 (de) 2000-05-04
NZ238208A (en) 1993-01-27
CA2083271A1 (fr) 1991-11-22
RU2109750C1 (ru) 1998-04-27
FI925296A7 (fi) 1992-11-20
JPH05508766A (ja) 1993-12-09
EP0651799B1 (fr) 1999-08-18
US5965383A (en) 1999-10-12
HU216302B (hu) 1999-06-28
EP0651799A4 (fr) 1993-10-05
WO1991017765A1 (fr) 1991-11-28
US6121426A (en) 2000-09-19
US5270030A (en) 1993-12-14
AU8076091A (en) 1991-12-10
JP3419772B2 (ja) 2003-06-23
HU9203516D0 (en) 1993-04-28
FI108298B (fi) 2001-12-31
HK1013255A1 (en) 1999-08-20

Similar Documents

Publication Publication Date Title
DK0651799T3 (da) Fibrinbindende domæne-polypeptider, anvendelser heraf og fremgangsmåder til fremstilling heraf
RU92016360A (ru) Визуализирующий агент, композиция, способ обнаружения материала, плазмиды, клетка, способы получения полипептида, полипептид, способ восстановления конформации полипептида
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
FI862756A0 (fi) Fibroektiner.
ATE182896T1 (de) Verfahren zur herstellung und auswahl von peptiden mit spezifischen eigenschaften
DK601786A (da) Hidtil ukendte prokoagulationsproteiner
WO1996017924A3 (fr) Nouveaux polypeptides issus d'une structure dite 'en herisson'
DK0464533T3 (da) Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
DE3166150D1 (en) N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation
DE69434538D1 (de) Vaskularer endothelialer wachstumsfaktor 2
KR870700019A (ko) 재조합 폐포 계면활성 단백질
RU93045577A (ru) Слитные полипептиды
DE3586773D1 (de) Verfahren zur beseitigung von n-endaminosaeureresten aus eukaryotpolypeptidanlagen und so erzeugte polypeptide.
DE69326559D1 (de) Rekombinante methode und wirt zur herstellung von xylitol
ATE108205T1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
DK450187D0 (da) Fremgangsmaade til fremstilling af proteiner
DK151585D0 (da) Dna-sekvens
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
DE68914397D1 (de) Menschliches Lymphotoxin.
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
DE69319831D1 (de) Methode zur Sequenzanalyse C-terminaler Peptidfragmente